Search

Your search keyword '"Kribben, Andreas"' showing total 1,124 results
Start Over Author "Kribben, Andreas"
1,124 results on '"Kribben, Andreas"'

1. Hemoadsorption therapy for myoglobin removal in rhabdomyolysis: consensus of the hemoadsorption in rhabdomyolysis task force

Author

Forni, Lui, Aucella, Filippo, Bottari, Gabriella, Büttner, Stefan, Cantaluppi, Vincenzo, Fries, Dietmar, Kielstein, Jan, Kindgen-Milles, Detlef, Krenn, Claus, Kribben, Andreas, Meiser, Andreas, Mitzner, Steffen, Ostermann, Marlies, Premuzic, Vedran, Rolfes, Caroline, Scharf, Christina, Schunk, Stefan, Molnar, Zsolt, and Zarbock, Alexander

Published
2024
Full Text
View/download PDF

4. Inhibiting the NADase CD38 improves cytomegalovirus-specific [CD8.sup.+] T cell functionality and metabolism

Author

Mulling, Nils, Behr, Felix M., Heieis, Graham A., Boss, Kristina, van Duikeren, Suzanne, van Haften, Floortje J., Pardieck, Iris N., van der Gracht, Esme T.I., Vleeshouwers, Ward, van der Sluis, Tetje C., de Graaf, J. Frederique, Veerkamp, Dominique M.B., Franken, Kees L.M.C., Lei, Xin, van de Sand, Lukas, van der Burg, Sjoerd H., Welters, Marij J.P., Heidt, Sebastiaan, Huisman, Wesley, Jochems, Simon P., Giera, Martin, Witzke, Oliver, de Vries, Aiko P.J., Kribben, Andreas, Everts, Bart, Wilde, Benjamin, and Arens, Ramon

Subjects
Physiological aspects, Health aspects, CD8 lymphocytes -- Health aspects, Glycoproteins -- Health aspects, Medical research, Metabolism -- Health aspects, Cytomegalovirus infections -- Physiological aspects, Medicine, Experimental
Abstract

Introduction Human cytomegalovirus (CMV) is one of the most encountered opportunistic viral pathogens in kidney transplant recipients (KTRs) (1). Although major advances in the treatment and prophylaxis of CMV-associated complications [...], Cytomegalovirus (CMV) is one of the most common and relevant opportunistic pathogens in people who are immunocompromised, such as kidney transplant recipients (KTRs). The exact mechanisms underlying the disability of cytotoxic T cells to provide sufficient protection against CMV in people who are immunosuppressed have not been identified yet. Here, we performed in-depth metabolic profiling of CMV-specific [CD8.sup.+] T cells in patients who are immunocompromised and show the development of metabolic dysregulation at the transcriptional, protein, and functional level of CMV-specific [CD8.sup.+] T cells in KTRs with noncontrolled CMV infection. These dysregulations comprise impaired glycolysis and increased mitochondrial stress, which is associated with an intensified expression of the nicotinamide adenine dinucleotide nucleotidase (NADase) CD38. Inhibiting NADase activity of CD38 reinvigorated the metabolism and improved cytokine production of CMV-specific [CD8.sup.+] T cells. These findings were corroborated in a mouse model of CMV infection under conditions of immunosuppression. Thus, dysregulated metabolic states of [CD8.sup.+] T cells could be targeted by inhibiting CD38 to reverse hyporesponsiveness in individuals who fail to control chronic viral infection.

Published
2024
Full Text
View/download PDF

9. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Author

Ostermann, Marlies, Bellomo, Rinaldo, Burdmann, Emmanuel A, Doi, Kent, Endre, Zoltan H, Goldstein, Stuart L, Kane-Gill, Sandra L, Liu, Kathleen D, Prowle, John R, Shaw, Andrew D, Srisawat, Nattachai, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C, Kellum, John A, Participants, Conference, Bagshaw, Sean M, Barreto, Erin F, Bihorac, Azra, Bobek, Ilona, Bouchard, Josée, Cerdá, Jorge, Chakravarthi, Rajasekara, De Rosa, Silvia, Engelman, Daniel T, Forni, Lui G, Hemmilä, Ulla K, Herzog, Charles A, Hoste, Eric A, Huen, Sarah C, Iseki, Kunitoshi, Joannidis, Michael, Kashani, Kianoush B, Koyner, Jay L, Kribben, Andreas, Lameire, Norbert, Levey, Andrew S, Macedo, Etienne, Małyszko, Jolanta, Meersch, Melanie, Mehta, Ravindra L, Mewburn, Irene, Mironova, Olga, Murray, Patrick T, Nadim, Mitra K, Pan, Jenny S, Pannu, Neesh, Peng, Zhiyong, Philips, Barbara, Ponce, Daniela, Ray, Patricio E, Ricci, Zaccaria, Rimmelé, Thomas, Ronco, Claudio, Siew, Edward D, Stevens, Paul E, Tolwani, Ashita J, Tonelli, Marcello, Vaara, Suvi T, van Dam, Marjel, Vijayan, Anitha, Wise, Michael, Wu, Vin-Cent, and Zarbock, Alexander

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Kidney Disease, 7.3 Management and decision making, Management of diseases and conditions, Renal and urogenital, Acute Kidney Injury, Humans, acute kidney disease, acute kidney injury, fluid management, nephrotoxicity, renal replacement therapy, risk stratification, Conference Participants, Urology & Nephrology, Clinical sciences
Abstract

In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) published a guideline on the classification and management of acute kidney injury (AKI). The guideline was derived from evidence available through February 2011. Since then, new evidence has emerged that has important implications for clinical practice in diagnosing and managing AKI. In April of 2019, KDIGO held a controversies conference entitled Acute Kidney Injury with the following goals: determine best practices and areas of uncertainty in treating AKI; review key relevant literature published since the 2012 KDIGO AKI guideline; address ongoing controversial issues; identify new topics or issues to be revisited for the next iteration of the KDIGO AKI guideline; and outline research needed to improve AKI management. Here, we present the findings of this conference and describe key areas that future guidelines may address.

Published
2020

12. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

Author

Özcan, Fedai, Markau, Silke, Girndt, Matthias, Felten, Helmut, Hausberg, Martin, Brand, Marcus, Gerth, Jens, Bommer, Martin, Zschiedrich, Stefan, Schneider, Johanna, Elitok, Saban, Gawlik, Alexander, Schwenger, Vedat, Roeder, Maximilian, Radermacher, Jörg, Morgner, Anke, Herbst, Regina, von Auer, Charis, Völker, Linus A., Kaufeld, Jessica, Balduin, Gesa, Merkel, Lena, Kühne, Lucas, Eichenauer, Dennis A., Osterholt, Thomas, Hägele, Holger, Kann, Martin, Grundmann, Franziska, Kolbrink, Benedikt, Schulte, Kevin, Gäckler, Anja, Kribben, Andreas, Boss, Kristina, Potthoff, Sebastian A., Rump, Lars C., Schmidt, Tilman, Mühlfeld, Anja S., Schulmann, Karsten, Hermann, Matthias, Gaedeke, Jens, Sauerland, Kristin, Bramstedt, Jörn, Hinkel, Ulrich P., Miesbach, Wolfgang, Bauer, Frederic, Westhoff, Timm H., Bruck, Heike, Buxhofer-Ausch, Veronika, Müller, Tobias J., Wendt, Ralph, Harth, Ana, Schreiber, Adrian, Seelow, Evelyn, Tölle, Markus, Gohlisch, Christopher, Bieringer, Markus, Geuther, Gesa, Jabs, Wolfram J., Fischereder, Michael, von Bergwelt-Baildon, Anke, Schönermarck, Ulf, Knoebl, Paul, Menne, Jan, and Brinkkoetter, Paul T.

Published
2023
Full Text
View/download PDF

14. Sequential Vaccination Against Streptococcus pneumoniae Appears as Immunologically Safe in Clinically Stable Kidney Transplant Recipients.

Author

Lindemann, Monika, van de Sand, Lukas, Mülling, Nils, Völk, Kim L., Aufderhorst, Ulrich W., Wilde, Benjamin, Horn, Peter A., Kribben, Andreas, Krawczyk, Adalbert, Witzke, Oliver, and Heinemann, Falko M.

Subjects
STREPTOCOCCUS pneumoniae, PNEUMOCOCCAL vaccines, GRAFT rejection, SEQUENTIAL analysis, KIDNEY physiology
Abstract

Background: Vaccination against Streptococcus pneumoniae is advised for transplant recipients to reduce morbidity and mortality associated with invasive pneumococcal disease. However, data on alloantibodies after sequential vaccination (with a pneumococcal conjugate vaccine followed by a polysaccharide vaccine) are still lacking. Methods: In the current study, we determined HLA class I and II and major histocompatibility class I-related chain A (MICA) antibodies in 41 clinically stable kidney transplant recipients. These antibodies were measured prior to and post sequential pneumococcal vaccination over a period of 12 months. Alloantibodies were measured by Luminex bead-based assays, and pneumococcal IgG antibodies were measured by ELISA. Results: Over a 12-month period, the sequential analysis revealed no significant change in alloantibodies. One patient developed de novo donor-specific antibodies (DSA) 1.5 months after the first vaccination, with mean fluorescence intensities of up to 2300. These DSA became undetectable in the follow-up, and the patient showed no signs of allograft rejection. Another patient experienced a biopsy-proven borderline rejection 7 months after the first vaccination but did not develop de novo DSA. Both maintained stable kidney function. As expected, the pneumococcal antibodies increased significantly after vaccination (p < 0.0001). Conclusions: Given the overall risk of alloimmune responses in transplant recipients, we would not attribute the two noticeable patient courses to vaccination. Thus, we consider sequential vaccination immunologically safe. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Results of the prospective multicenter SoLKiD cohort study indicate bio-psycho-social outcome risks to kidney donors 12 months after donation

Author

Koch, Martina, Kröncke, Sylvia, Weimer, Rolf, Rainer, Lucy, Sommerer, Claudia, Zeier, Martin, Budde, Klemens, Halleck, Fabian, Ivens, Katrin, Hansen, Anita, Reinke, Petra, Pascher, Andreas, Mühlfeld, Anja, Floege, Jürgen, Wahba, Roger, Vitinius, Frank, Kribben, Andreas, Eisenberger, Ute, Hugo, Christian, Quick, Carmen, Nitschke, Martin, Derad, Inge, Rath, Thomas, Mönch, Christian, Schiffer, Mario, Güler, Faikal, Krüger, Bernd, Bönnighoff, Roderich, Hauser, Ingeborg, Platschek, Steffen, Lopau, Kai, Pein, Ulrich, Weigand, Karl, Feldkamp, Thorsten, Kunzendorf, Ulrich, Suwelack, Barbara, Berger, Klaus, Wolters, Heiner, Gerß, Joachim W.O., Bormann, Eike, Wörmann, Viktorya, and Burgmer, Markus

Published
2022
Full Text
View/download PDF

17. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference

Author

Caskey, Fergus J., Farmer, Chris K.T., Ferreiro Fuentes, Alejandro, Fukagawa, Masafumi, Goldstein, Stuart L., Igiraneza, Grace, Kribben, Andreas, Lerma, Edgar V., Levey, Andrew S., Liu, Kathleen D., Małyszko, Jolanta, Ostermann, Marlies, Pannu, Neesh, Ronco, Claudio, Sawhney, Simon, Shaw, Andrew D., Srisawat, Nattachai, Lameire, Norbert H., Levin, Adeera, Kellum, John A., Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Stevens, Paul E.

Published
2021
Full Text
View/download PDF

19. Primidone blocks RIPK1-driven cell death and inflammation

Author

Riebeling, Theresa, Jamal, Kunzah, Wilson, Rebecca, Kolbrink, Benedikt, von Samson-Himmelstjerna, Friedrich Alexander, Moerke, Caroline, Ramos Garcia, Laura, Dahlke, Eileen, Michels, Friederike, Lühder, Fred, Schunk, Domagoj, Doldi, Philipp, Tyczynski, Bartosz, Kribben, Andreas, Flüh, Charlotte, Theilig, Franziska, Kunzendorf, Ulrich, Meier, Pascal, and Krautwald, Stefan

Published
2021
Full Text
View/download PDF

20. Effect of Difference in Serum Creatinine between Jaffe and Enzymatic Methods in Outpatient Kidney Transplant Recipients.

Author

Boss, Kristina, Stolpe, Susanne, Müller, André, Friebus-Kardash, Justa, Wagner, Bernd, Wichert, Marc, Assert, Roland, Volbracht, Lothar, Stang, Andreas, Kowall, Bernd, and Kribben, Andreas

Subjects
CHRONIC kidney failure, KIDNEY transplantation, KIDNEY diseases, EPIDERMAL growth factor receptors, UNIVERSITY hospitals
Abstract

Highlights: What was known: Deviations in serum creatinine (SCr), due to its determination using a Jaffe or an enzymatic method, have an effect on kidney disease detection and staging. It is not yet clear how large this effect is in kidney transplant recipients (KTRs). SCr measurement differences are of particular importance here to evaluate the graft function. This study adds: Investigation of the difference between Jaffe SCr and enzymatic SCr in a large cohort of outpatient KTRs. In more than every tenth SCr determination in outpatient KTRs, the difference between the Jaffe and enzymatic methods had an influence on the assignment to a CKD stage. This effect was comparably pronounced for all eGFR formulas applied. Potential impact: Clinicians should keep in mind that the difference between Jaffe and enzymatic SCr affects CKD staging in KTRs. Background: Deviations in serum creatinine (SCr), due to its determination using a Jaffe or an enzymatic method, have an effect on kidney disease detection and staging. It is not yet clear how large this effect is in kidney transplant recipients (KTRs). SCr measurement differences are of particular importance here to evaluate the graft function. Methods: The results of all parallel SCr measurements (Jaffe and enzymatic method) of adult outpatient KTRs in the same serum sample at the University Hospital Essen (Germany) between January 2020 and October 2023 were evaluated. A Bland–Altman plot with 95% limits of agreement (LoA) was used to assess the difference between the Jaffe and the enzymatic SCr (eSCr). For all patients, we used the CKD-EPI 2009 and EKFC formula, and for patients ≥ 70 years, we also used the BIS1 formula for the determination of eGFR. Results: A total of 12,081 parallel SCr measurements from 1243 KTRs were analyzed, where 61% were male and the median age was 53 years. On average, Jaffe SCr was 0.03 mg/dL higher than eSCr (LoA −0.16; 0.21 mg/dL). On average, the eGFR determined by Jaffe SCr was 1.9 mL/min/1.73 m2 lower than the eGFR determined by eSCr (LoA −9.5; 5.7 mL/min/1.73 m2). The comparison of eGFR between the two SCr methods revealed a different CKD stage in 1589 (13%) of all analyzed measurements, most frequently between G2/G3a (41%) and G3a/G3b (24%). When using the EKFC and BIS1 formulas, there were approximately the same number of measurements leading to a different CKD stage. Conclusions: In more than every tenth SCr determination in outpatient KTRs, the difference between the Jaffe and enzymatic methods had an influence on the assignment to a CKD stage. This effect was comparably pronounced for all eGFR formulas applied. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients.

Author

Schönfelder, Kristina, Möhlendick, Birte, Eisenberger, Ute, Kribben, Andreas, Siffert, Winfried, Heinemann, Falko M., Gäckler, Anja, Wilde, Benjamin, and Friebus-Kardash, Justa

Subjects
KIDNEY transplantation, GRAFT rejection, CYTOCHROME P-450 CYP3A, TACROLIMUS, GENETIC polymorphisms
Abstract

Background/Objectives: Our previous retrospective single-center cohort study found, at 3-year follow-up, a trend toward low tacrolimus trough levels and an increased risk of de novo donor-specific anti-HLA antibodies (DSAs) and of antibody-mediated rejection (ABMR) in CYP3A5-expressing patients. Determining CYP3A5-expression status immediately after renal transplant would allow early genotype-based dosage adjustment of tacrolimus and might prevent the occurrence of de novo DSAs and ABMR, improving transplant outcome. Methods: 160 renal allograft recipients who underwent renal transplant at the University Hospital Essen between May 2019 and May 2022 were genotyped for the CYP3A5 rs776746 polymorphism within the first two weeks after transplant, and genotype-based dose adjustment of tacrolimus was performed for the follow-up of 2 years. Results: CYP3A5 expression was detected in 33 (21%) of the 160 patients. Tacrolimus trough levels were similar in CYP3A5 expressers and nonexpressers over the entire 2-year follow-up period. However, we observed a trend toward slightly higher tacrolimus trough levels in CYP3A5 expressers, who, as expected, required tacrolimus dosages twice as high as did nonexpressers during follow-up. Calcineurin inhibitor (CNI) nephrotoxicity-free survival rates were comparable between CYP3A5 expressers and nonexpressers (p = 0.49). Rejection-free survival rates (p = 0.89), de novo anti-HLA antibody-free survival rates (p = 0.57) and de novo DSA-free survival rates (p = 0.61) did not differ between the two groups. Conclusions: Early detection of CYP3A5-expression status and resultant genotype-based adjustment of tacrolimus dosage after renal transplant protected patients from transplant rejection and de novo DSA formation and was not associated with increased incidence of CNI toxicity among CYP3A5 expressers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Author

Bagshaw, Sean M., Barreto, Erin F., Bihorac, Azra, Bobek, Ilona, Bouchard, Josée, Cerdá, Jorge, Chakravarthi, Rajasekara, De Rosa, Silvia, Engelman, Daniel T., Forni, Lui G., Hemmilä, Ulla K., Herzog, Charles A., Hoste, Eric A., Huen, Sarah C., Iseki, Kunitoshi, Joannidis, Michael, Kashani, Kianoush B., Koyner, Jay L., Kribben, Andreas, Lameire, Norbert, Levey, Andrew S., Macedo, Etienne, Małyszko, Jolanta, Meersch, Melanie, Mehta, Ravindra L., Mewburn, Irene, Mironova, Olga, Murray, Patrick T., Nadim, Mitra K., Pan, Jenny S., Pannu, Neesh, Peng, Zhiyong, Philips, Barbara, Ponce, Daniela, Ray, Patricio E., Ricci, Zaccaria, Rimmelé, Thomas, Ronco, Claudio, Siew, Edward D., Stevens, Paul E., Tolwani, Ashita J., Tonelli, Marcello, Vaara, Suvi T., van Dam, Marjel, Vijayan, Anitha, Wise, Michael, Wu, Vin-Cent, Zarbock, Alexander, Ostermann, Marlies, Bellomo, Rinaldo, Burdmann, Emmanuel A., Doi, Kent, Endre, Zoltan H., Goldstein, Stuart L., Kane-Gill, Sandra L., Liu, Kathleen D., Prowle, John R., Shaw, Andrew D., Srisawat, Nattachai, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Kellum, John A.

Published
2020
Full Text
View/download PDF

23. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

Author

Völker, Linus A., Kaufeld, Jessica, Miesbach, Wolfgang, Brähler, Sebastian, Reinhardt, Martin, Kühne, Lucas, Mühlfeld, Anja, Schreiber, Adrian, Gaedeke, Jens, Tölle, Markus, Jabs, Wolfram J., Özcan, Fedai, Markau, Silke, Girndt, Matthias, Bauer, Frederic, Westhoff, Timm H., Felten, Helmut, Hausberg, Martin, Brand, Marcus, Gerth, Jens, Bieringer, Markus, Bommer, Martin, Zschiedrich, Stefan, Schneider, Johanna, Elitok, Saban, Gawlik, Alexander, Gäckler, Anja, Kribben, Andreas, Schwenger, Vedat, Schoenermarck, Ulf, Roeder, Maximilian, Radermacher, Jörg, Bramstedt, Jörn, Morgner, Anke, Herbst, Regina, Harth, Ana, Potthoff, Sebastian A., von Auer, Charis, Wendt, Ralph, Christ, Hildegard, Brinkkoetter, Paul T., and Menne, Jan

Published
2020
Full Text
View/download PDF

24. ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

Author

Völker, Linus A., Kaufeld, Jessica, Miesbach, Wolfgang, Brähler, Sebastian, Reinhardt, Martin, Kühne, Lucas, Mühlfeld, Anja, Schreiber, Adrian, Gaedeke, Jens, Tölle, Markus, Jabs, Wolfram J., Özcan, Fedai, Markau, Silke, Girndt, Matthias, Bauer, Frederic, Westhoff, Timm H., Felten, Helmut, Hausberg, Martin, Brand, Marcus, Gerth, Jens, Bieringer, Markus, Bommer, Martin, Zschiedrich, Stefan, Schneider, Johanna, Elitok, Saban, Gawlik, Alexander, Gäckler, Anja, Kribben, Andreas, Schwenger, Vedat, Schoenermarck, Ulf, Roeder, Maximilian, Radermacher, Jörg, Bramstedt, Jörn, Morgner, Anke, Herbst, Regina, Harth, Ana, Potthoff, Sebastian A., von Auer, Charis, Wendt, Ralph, Christ, Hildegard, Brinkkoetter, Paul T., and Menne, Jan

Published
2020
Full Text
View/download PDF

26. Urinary Biomarkers for Cell Cycle Arrest TIMP-2 and IGFBP7 for Prediction of Graft Function Recovery after Kidney Transplantation

Author

Gäckler, Anja, primary, Ertasoglu, Onurcan, additional, Rohn, Hana, additional, Friebus-Kardash, Justa, additional, Ickerott, Philipp-Christopher, additional, Witzke, Oliver, additional, Kribben, Andreas, additional, Vogt, Bruno, additional, Dahdal, Suzan, additional, Arampatzis, Spyridon, additional, and Eisenberger, Ute, additional

Published
2024
Full Text
View/download PDF

43. Reimbursement of Dialysis: A Comparison of Seven Countries

Author

Vanholder, Raymond, Davenport, Andrew, Hannedouche, Thierry, Kooman, Jeroen, Kribben, Andreas, Lameire, Norbert, Lonnemann, Gerhard, Magner, Peter, Mendelssohn, David, Saggi, Subodh J, Shaffer, Rachel N, Moe, Sharon M, Van Biesen, Wim, van der Sande, Frank, Mehrotra, Rajnish, and Society of Nephrology, on behalf of the Dialysis Advisory Group of the American

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Kidney Disease, Good Health and Well Being, Europe, Humans, Kidney Failure, Chronic, Ontario, Reimbursement Mechanisms, Renal Dialysis, United States, Dialysis Advisory Group of American Society of Nephrology, Urology & Nephrology, Clinical sciences
Abstract

Reimbursement for chronic dialysis consumes a substantial portion of healthcare costs for a relatively small proportion of the total population. Each country has a unique reimbursement system that attempts to control rising costs. Thus, comparing the reimbursement systems between countries might be helpful to find solutions to minimize costs to society without jeopardizing quality of treatment and outcomes. We conducted a survey of seven countries to compare crude reimbursement for various dialysis modalities and evaluated additional factors, such as inclusion of drugs or physician payments in the reimbursement package, adjustment in rates for specific patient subgroups, and pay for performance therapeutic thresholds. The comparison examines the United States, the province of Ontario in Canada, and five European countries (Belgium, France, Germany, The Netherlands, and the United Kingdom). Important differences between countries exist, resulting in as much as a 3.3-fold difference between highest and lowest reimbursement rates for chronic hemodialysis. Differences persist even when our data were adjusted for per capita gross domestic product. Reimbursement for peritoneal dialysis is lower in most countries except Germany and the United States. The United Kingdom is the only country that has implemented an incentive if patients use an arteriovenous fistula. Although home hemodialysis (prolonged or daily dialysis) allows greater flexibility and better patient outcomes, reimbursement is only incentivized in The Netherlands. Unfortunately, it is not yet clear that such differences save money or improve quality of care. Future research should focus on directly testing both outcomes.

Published
2012

49. Association of high HLA-E expression during acute cellular rejection and numbers of HLA class I leader peptide mismatches with reduced renal allograft survival

Author

Guberina, Hana, Rebmann, Vera, Wagner, Bettina, da Silva Nardi, Fabiola, Dziallas, Phillip, Dolff, Sebastian, Bienholz, Anja, Wohlschlaeger, Jeremias, Bankfalvi, Agnes, Heinemann, Falko M., Witzke, Oliver, Zoet, Yvonne M., Claas, Frans H.J., Horn, Peter A., Kribben, Andreas, and Doxiadis, Ilias I.N.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results